Landmark Study Aims to Improve Osteoporosis Care Standards Worldwide.
ISTANBUL, Turkey, April 10 /PRNewswire/ --
- Multi-national study will follow 60,000 women for 5 years
Nearly 60,000 women aged 55 years and older have enrolled in a landmark, multi-national study that will focus on the management of osteoporosis across the globe. Launch of the Global Longitudinal Registry of Osteoporosis in Women (GLOW) was announced today at ECCEO 8 (Eighth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis osteoarthritis
or osteoarthrosis or degenerative joint disease
Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. ) in Istanbul, Turkey. This groundbreaking observational study (registry) in osteoporosis aims to gain insights to improve the standard of care for postmenopausal post·men·o·paus·al
Of or occurring in the time following menopause.
postmenopausal Change of life Gynecology adjective Referring to the time in ♀ when menstrual periods stop for ≥ 1 yr women at risk of osteoporosis.
"We know that there are patients at high risk for osteoporosis, sometimes already having suffered a broken bone, who aren't getting diagnosed and treated. We have to figure out why not," said Dr. Robert Lindsay Robert Lindsay is the name of several people:
Causing a loss of strength or energy.
Weakening, or reducing the strength of.
Mentioned in: Stress Reduction disease."
GLOW will monitor tens of thousands of older women who have visited a primary care physician in the past two years. Since patient recruitment for GLOW is not linked to osteoporosis diagnosis and does not alter physician practice, the study provides a good representation of "typical" older women and the bone health care they receive in the real world. Women are participating from 17 cities in 10 countries on 3 continents.
"We want to understand regional differences in physician and patient behavior and how that impacts patient outcomes," said Professor Pierre Delmas, GLOW Executive Committee Co-Chair and Professor of Medicine and Rheumatology rheumatology /rheu·ma·tol·o·gy/ (-tol´ah-je) the branch of medicine dealing with rheumatic disorders, their causes, pathology, diagnosis, treatment, etc.
n. , UniversitA[c] Claude Bernard, Lyon, France. "Hopefully, armed with that knowledge we will be able to recommend best practices and improve the management of osteoporosis worldwide."
GLOW is being conducted by The Center for Outcomes Research (COR), University of Massachusetts Medical School UMMS is ranked fourth in primary care education among the nation’s 125 medical schools in the 2006 U.S.News & World Report annual guide, “America’s Best Graduate Schools”. UMMS is also a major center for research. (UMMS UMMS University of Massachusetts Medical School (North Worcester, Massachusetts)
UMMS University of Maryland Medical System
UMMS United Methodist Missionary Society ), with the support of an unrestricted research grant from The Alliance for Better Bone Health. The Alliance for Better Bone Health is a collaboration between sanofi-aventis and Procter & Gamble Pharmaceuticals.
"We are grateful for the commitment of the sponsors and scientific advisors to the GLOW project. We anticipate that these data will provide important information to improve the quality of lives of women at risk for osteoporotic fractures," said Dr. Fred Anderson Fred Anderson is the name of a number of notable people, including:
Milestone data from GLOW will be communicated on an ongoing basis at international medical conferences and through peer-reviewed publications. For more information on GLOW, please visit: http://www.outcomes.org/glow/
GLOW is a prospective, longitudinal, observational study of women over 55 years of age who visited a primary care physician during the two years prior to the study. Women were recruited through 700 primary care physicians in 17 cities in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. , Europe, and Australia. GLOW will gather information on osteoporosis risk factors, treatment approaches, patient behavior, and fracture outcomes with an annual patient survey over a 5 year period.
GLOW study sites are the following:
West Haverstraw, NY USA
Worcester, MA USA
Pittsburgh, PA USA
Seattle, WA USA
Cincinnati, OH USA
Los Angeles, CA USA
Birmingham, AL USA
Hamilton, Ontario Canada
Notes to Editors
Spokespeople available for comment:
Dr. Robert Lindsay
Executive committee co-chair, GLOW
Chief of Internal Medicine at Helen Hayes Hospital, West Haverstraw, NY
Professor Pierre Delmas
Executive committee co-chair, GLOW
Professor of medicine and rheumatology, UniversitA[c] Claude Bernard, Lyon, France
Osteoporosis-related fragility fractures are an international public health problem responsible for increased mortality, functional impairment and added health care costs. Estimates are that between 40 and 50 percent of white women above the age of 50 in North America, Europe and Australia will incur an osteoporosis-related fracture in their lifetime. Although their rates are lower, non-white women and men are also susceptible. Because the likelihood of fragility fractures increases dramatically with age, fracture numbers are projected to rise as the population ages.
About the Center for Outcomes Research (COR)
COR is based at the University of Massachusetts The system includes UMass Amherst, UMass Boston, UMass Dartmouth (affiliated with Cape Cod Community College), UMass Lowell, and the UMass Medical School. It also has an online school called UMassOnline. , Worcester, MA, USA. The mission of COR is to collect and evaluate data that reflect real world practices and outcomes and to provide physicians with confidential reports that allow comparison of their practices to evidence based performance standards. For more information, please visit: http://www.outcomes.org
For further information: Helen Crow, Ketchum, Tel: +44(0)7787-533-023, Email: email@example.com; Peter Impey, Ketchum, Tel: +44(0)7976-734-493, Email: firstname.lastname@example.org